Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years
Portfolio Pulse from Vandana Singh
Vera Therapeutics Inc. (NASDAQ:VERA) announced positive results from its ORIGIN Phase 2b trial of atacicept for IgA nephropathy, showing sustained kidney function improvement over 96 weeks. The data supports the potential for long-term disease modification and boosts confidence in the ongoing Phase 3 trial. VERA stock rose 12.2% following the announcement.
October 28, 2024 | 2:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vera Therapeutics' atacicept demonstrated significant improvement in kidney function for IgA nephropathy patients over 96 weeks, supporting its potential for long-term disease modification. This positive data boosts confidence in the ongoing Phase 3 trial and has led to a 12.2% increase in VERA stock.
The positive results from the Phase 2b trial of atacicept in IgA nephropathy patients indicate potential for long-term disease modification, which is a significant development for Vera Therapeutics. The data supports the ongoing Phase 3 trial, and the stock price has already reacted positively with a 12.2% increase, reflecting investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100